Large Study Finds GLP-1 Agonists Reduce Heart Failure Risk in Diabetes

Incretin-based drugs, a class including GLP-1 receptor agonists and DPP-4 inhibitors, are widely prescribed for managing Type 2 Diabetes Mellitus. While effective for glycemic control, there have been ongoing discussions and concerns regarding their potential impact on cardiovascular health, specifically the risk of heart failure (HF). This extensive observational study aimed to determine if the use of incretin-based drugs is associated with an increased or decreased risk of heart failure compared to other oral anti-diabetic drug combinations.

The study revealed differential impacts on heart failure (HF) risk among incretin-based drug classes. DPP-4 inhibitors were generally associated with a similar risk of HF compared to other oral anti-diabetic drugs; specifically, when compared to sulfonylureas, DPP-4 inhibitors showed a hazard ratio (HR) of 0.96 (95% CI 0.89-1.04), indicating no significant difference. In stark contrast, GLP-1 receptor agonists consistently demonstrated a protective effect. > For patients on GLP-1 receptor agonists, the risk of heart failure was significantly lower, showing an 18% reduction (HR 0.82, 95% CI 0.73-0.92) compared to those on sulfonylureas. This significant reduction in HF risk was also observed when GLP-1 receptor agonists were compared to other oral anti-diabetic drugs, with an HR of 0.82 (95% CI 0.74-0.91), highlighting their potential cardiovascular benefits.